IL6 and Andersen-Tawil syndrome: However, a broader investigation of the correlates of immune activation/inflammation during early vascular damage in HIV-infected patients receiving virologically suppressive cART failed to detect relevant differences in pro-inflammatory biomarkers and the endothelial adhesion marker sVCAM-1, with the exception of a non-significant trend towards higher circulating levels of IL-6 in patients with ATS.